FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292869368> ?p ?o ?g. }

• W4292869368 endingPage "362" @default.
• W4292869368 startingPage "359" @default.
• W4292869368 abstract "Therapeutic DeliveryAhead of Print EditorialOpen Access3D printing for the development of implantable devices for cardiovascular disease treatmentEneko Larrañeta, Juan Domínguez-Robles, Andriana Margariti, Abdul W Basit & Álvaro GoyanesEneko Larrañeta*Author for correspondence: E-mail Address: e.larraneta@qub.ac.ukSchool of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UKSearch for more papers by this author, Juan Domínguez-RoblesSchool of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UKSearch for more papers by this author, Andriana MargaritiWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, BT9 7BL, UKSearch for more papers by this author, Abdul W BasitUCL School of Pharmacy, University College London, 29–39 Brunswick Square, London, WC1N 1AX, UKFabRx Ltd., Henwood House, Henwood, Ashford, Kent, TN24 8DH, UKSearch for more papers by this author & Álvaro GoyanesUCL School of Pharmacy, University College London, 29–39 Brunswick Square, London, WC1N 1AX, UKFabRx Ltd., Henwood House, Henwood, Ashford, Kent, TN24 8DH, UKDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia & Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, 15782, SpainSearch for more papers by this authorPublished Online:24 Aug 2022https://doi.org/10.4155/tde-2022-0017AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail Keywords: 3D printingadditive manufacturingbioprintingcardiovascular diseasestentvascular graftAdditive manufacturing (also known as 3D printing) has proven to be an effective technology for pharmaceutical and biomedical applications [1,2]. Additive manufacturing is a family of technologies used to prepare 3D objects by adding layers of material in a sequential way [1]. Typically, 3D-printing techniques are classified according to the mechanism followed to add the layers of materials including photopolymerization, sintering or extrusion, among many others [1]. Accordingly, additive manufacturing offers a high degree of flexibility in terms of techniques and materials. In the last decade, there has been growing interest in the use of additive manufacturing for pharmaceutical and medical applications [1,2]. One of the key advantages over conventional methods of manufacturing is that additive manufacturing can be used to prepare dosage forms adapted to patients' needs [3]. In addition to its versatility, another factor that has contributed to the interest of the scientific community in 3D printing in research laboratories is its availability. Over the past decade, the price of certain types of 3D printers (mainly stereolithography and fused deposition modeling) has significantly dropped. Due to these factors, a wide range of dosage forms has been produced using 3D printing, including tablets, capsules and suppositories, among many other examples [4–6]. As a result of extensive work, the first 3D-printed pharmaceutical product (Spritam®) approved by the US FDA was introduced to the market in 2016 [7]. In addition to pharmaceutical products, 3D printing has also been used to fabricate medical devices such as implants for drug delivery, orthopedic prostheses, medicated catheters or cardiovascular stents, among many others [8–12]. This editorial is focused on 3D-printed medical devices for the treatment of cardiovascular diseases (CVDs).CVD is an umbrella term used to define a set of diseases affecting the blood vessels and/or the heart [13]. Currently, CVD is the leading cause of death globally and contributes actively to a reduction in the quality of life of patients suffering from it [13]. A wide variety of therapeutic options are available to treat CVD, including surgical and pharmacological treatments [13]. Surgical procedures often involve the use of medical devices, such as vascular stents or synthetic vascular grafts [2]. As mentioned, the production of such devices can be accomplished using 3D-printing technology [2,14–16]. In this regard, 3D printing offers a high degree of flexibility, as devices can be adapted to the patient's anatomy, wherein the computer design can be attained using medical imaging techniques such as computed tomography or MRI. The scientific literature includes several examples of 3D-printed implantable devices designed to treat CVD. These can be classified into medical devices (e.g., stents and vascular prostheses) and tissue engineering-based devices. The latter have gained interest in recent years due to the rapid development of 3D bioprinting.3D-printed implantable devices used to treat cardiovascular diseasesCardiovascular stents are heavily used to treat coronary artery disease. These devices are implanted in narrowed arteries to expand the lumen to ensure appropriate blood flow [10]. Cardiovascular stents are conventionally made of metal and, in some cases, are coated with different formulations to load drugs onto them [10]. In this way, antiproliferative or antiplatelet drugs can be released into the target site to prevent restenosis or the formation of blood clots [10]. The production of stents using additive manufacturing techniques has been extensively reported. These devices have been produced using a majority of 3D-printing techniques, including high-end equipment such as two-photon polymerization and the more affordable fused deposition modeling printers [10]. Although these devices are mainly produced for research purposes, some studies evaluated the use of 3D printing to produce implantable patient-specific stents in hospitals [17]. This could reduce the supply time from around 150 days to just 20 min. Stents produced via additive manufacturing have been successfully prepared using a wide variety of materials such as poly(caprolactone), poly(propylene), poly(lactic acid) and a variety of photo-crosslinkable resins. Some of these stents have shown comparable mechanical properties to commercially available stents. However, these devices have only been tested in vitro or using animal models. Therefore, more research is needed to ensure the safety and efficacy of these devices.Vascular grafts are tubular prostheses used to redirect blood around a blocked artery within the heart. These grafts can be blood vessels harvested from the patient's leg or can be synthetic prostheses. Vascular grafts have been prepared using 3D printing. Mainly, stereolithography and extrusion-based additive manufacturing technologies have been used to prepare vascular grafts. These grafts are made of biodegradable polymers, such as poly(caprolactone) or poly(propylene fumarate) [14,18,19], or nonbiodegradable polymers, such as thermoplastic polyurethane [15,20]. The resulting prostheses present similar or superior mechanical properties compared with native blood vessels while supporting the growth of endothelial cells [14,18,20]. Additionally, drugs such as dipyridamole or acetylsalicylic acid can be combined with the polymers to obtain vascular grafts capable of preventing platelet adhesion [14,19,20]. Despite some of these devices being successfully tested in animal models showing that 3D-printed grafts maintained functionality for periods of at least 6 months [18], more work is needed before they can be used in clinical trials.In addition to the production of solid devices like the ones previously described, there is growing interest in developing soft cell-laden materials mimicking biological tissue for 3D printing applications. This is also known as 3D bioprinting. The aim of this technology is to produce implants loaded with cells for tissue regeneration [21]. Cell-based repair and regeneration of healthy vascular cells/tissues is a major focus in regenerative medicine to improve CVD. Stem cell technologies are aiding in the advancement of regenerative medicine by providing patient-derived disease models of vascular cells. Due to the differentiation capabilities of stem cells, reprogramming technologies offer approaches to developing patient-specific disease models [22]. For this purpose, hydrogels such as gelatine or hyaluronic acid are used [21]. They are normally loaded with cells prior to the 3D-printing process, followed by the use of extrusion-based additive manufacturing to add layers of these gels. Due to the flow properties of these materials, in some cases, an extra crosslinking step is needed to maintain the structure of the printed object. In this case, modified polymers with reactive groups (e.g., methacrylate groups) and photoinitiators are required [21]. However, these compounds should be cytocompatible to maintain the integrity of the cells during the printing process. These types of materials can be 3D-printed using photopolymerization-based technologies. To date, a variety of 3D-printed cardiovascular tissues such as blood vessels and myocardium have been manufactured yielding tissues capable of cell adhesion, proliferation, differentiation and even cell migration. Nevertheless, this technology is still in development and more work is needed before fully functional 3D-printed tissues can be produced.Future perspective3D printing is a disruptive manufacturing technology that has shown great potential in several industries. Healthcare applications of this technology are being extensively studied by researchers and companies. Due to these substantial efforts, the FDA has approved several 3D-printed pharmaceutical and medical devices in recent years, such as Spiritam, a rapidly dissolving levetiracetam tablet and FLX™ implants to support the spine. One of the key benefits of 3D printing is its ability to be applied at the point of care, allowing the development of personalized implants and therapies. Pioneering works in this area have been reported for the production of customized oral dosage forms and cranial plates in hospitals and clinics. In addition to these applications, there is a clear interest in the development of bespoke devices for the treatment of CVD, as well as cell-loaded implants for tissue regeneration. The use of a personalized approach allows for site-specific drug delivery with proper adhesion while reducing adverse events and achieving efficient treatment. This is particularly important in CVD, as a large number of the drugs used for the treatment of CVD, such as digoxin or warfarin among many others, have a narrow therapeutic index (i.e., a small range between the effective and toxic dose), making it crucial to control the drug dose based on the patient's genetic makeup and disease condition.Despite the promising clinical applications of 3D printing, there remain some regulatory issues relating to quality control and quality assurance of 3D-printed devices that must be addressed before their adoption. Additionally, some of the materials used for 3D-printing applications are not FDA approved, limiting the applicability of some of these technologies. Another concern with the development of implantable devices is their sterility, wherein they must be prepared under aseptic conditions or sterilized prior to their implantation. Accordingly, more studies on the effect of sterilization conditions on 3D-printed materials are needed. The FDA is working closely with researchers and, accordingly, has provided some guidance for the development of medical devices using 3D-printing technologies. In a similar manner, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom will be modifying regulations to include tissue-engineered products and 3D printing at the point of care. This is just the beginning, as the conversation between regulatory agencies and different pharmaceutical stakeholders is taking place to address challenges and concerns relating to innovative pharmaceutical approaches. Accordingly, it is likely that more 3D-printed medical device products will be released to the market in the next few years.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0References1. Seoane-Viaño I, Trenfield SJ, Basit AW, Goyanes A. Translating 3D printed pharmaceuticals: from hype to real-world clinical applications. Adv. Drug Deliv. Rev. 174, 553–575 (2021).Crossref, Medline, CAS, Google Scholar2. Gharleghi R, Dessalles CA, Lal R et al. 3D printing for cardiovascular applications: from end-to-end processes to emerging developments. Ann. Biomed. Eng. 49(7), 1598–1618 (2021).Crossref, Medline, Google Scholar3. Goyanes A, Madla CM, Umerji A et al. Automated therapy preparation of isoleucine formulations using 3D printing for the treatment of MSUD: first single-centre, prospective, crossover study in patients. Int. J. Pharm. 567, 118497 (2019).Crossref, Medline, CAS, Google Scholar4. Seoane-Viaño I, Gómez-Lado N, Lázare-Iglesias H et al. 3D printed tacrolimus rectal formulations ameliorate colitis in an experimental animal model of inflammatory bowel disease. Biomedicines 8(12), 563 (2020).Crossref, CAS, Google Scholar5. Russi L, Del Gaudio C. 3D printed multicompartmental capsules for a progressive drug release. Ann. 3D Print. Med. 3, 100026 (2021).Crossref, Google Scholar6. Xu X, Seijo-Rabina A, Awad A et al. Smartphone-enabled 3D printing of medicines. Int. J. Pharm. 609, 121199 (2021).Crossref, Medline, CAS, Google Scholar7. Muñiz Castro B, Elbadawi M, Ong JJ et al. Machine learning predicts 3D printing performance of over 900 drug delivery systems. J. Control. Rel. 337, 530–545 (2021).Crossref, Medline, Google Scholar8. Stewart SA, Domínguez-Robles J, McIlorum VJ et al. Poly(caprolactone)-based coatings on 3D-printed biodegradable implants: a novel strategy to prolong delivery of hydrophilic drugs. Mol. Pharm. 17(9), 3487–3500 (2020).Crossref, Medline, CAS, Google Scholar9. Wixted CM, Peterson JR, Kadakia RJ, Adams SB. Three-dimensional printing in orthopaedic surgery: current applications and future developments. JAAOS Glob. Res. Rev. 5(4), e20.00230–11 (2021).Crossref, Google Scholar10. Khalaj R, Tabriz AG, Okereke MI, Douroumis D. 3D printing advances in the development of stents. Int. J. Pharm. 609, 121153 (2021).Crossref, Medline, CAS, Google Scholar11. Mathew E, Domí­nguez-Robles J, Stewart SA et al. Fused deposition modeling as an effective tool for anti-infective dialysis catheter fabrication. ACS Biomater. Sci. Eng. 5(11), 6300–6310 (2019).Crossref, Medline, CAS, Google Scholar12. Picco CJ, Domínguez-Robles J, Utomo E et al. 3D-printed implantable devices with biodegradable rate-controlling membrane for sustained delivery of hydrophobic drugs. Drug Deliv. 29(1), 1038–1048 (2022).Crossref, Medline, CAS, Google Scholar13. Roth GA, Mensah GA, Johnson CO et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J. Am. Coll. Cardiol. 76(25), 2982–3021 (2020).Crossref, Medline, Google Scholar14. Domínguez-Robles J, Shen T, Cornelius VA et al. Development of drug-loaded cardiovascular prosthesis for thrombosis prevention using 3D printing. Mater. Sci. Eng. C 129, 112375 (2021).Crossref, Medline, CAS, Google Scholar15. Martin NK, Domínguez-Robles J, Stewart SA et al. Fused deposition modeling for the development of drug-loaded cardiovascular prosthesis. Int. J. Pharm. 595, 120243 (2021).Crossref, Medline, CAS, Google Scholar16. Bloomquist CJ, Mecham MB, Paradzinsky MD et al. Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins. J. Control. Rel. 278, 9–23 (2018).Crossref, Medline, CAS, Google Scholar17. Moore SS, O'Sullivan KJ, Verdecchia F. Shrinking the supply chain for implantable coronary stent devices. Ann. Biomed. Eng. 44(2), 497–507 (2016).Crossref, Medline, Google Scholar18. Melchiorri AJ, Hibino N, Best CA et al. 3D-printed biodegradable polymeric vascular grafts. Adv. Healthc. Mater. 5(3), 319–325 (2016).Crossref, Medline, CAS, Google Scholar19. Domínguez-Robles J, Diaz-Gomez L, Utomo E et al. Use of 3D printing for the development of biodegradable antiplatelet materials for cardiovascular applications. Pharmaceuticals 14(9), 921 (2021).Crossref, Medline, CAS, Google Scholar20. Domínguez-Robles J, Utomo E, Cornelius VA et al. TPU-based antiplatelet cardiovascular prostheses prepared using fused deposition modelling. Mater. Des. 220, 110837 (2022).Crossref, CAS, Google Scholar21. Sung K, Patel NR, Ashammakhi N, Nguyen K-L. 3-Dimensional bioprinting of cardiovascular tissues. JACC Basic Transl. Sci. 6(5), 467–482 (2021).Crossref, Medline, Google Scholar22. Yang C, Eleftheriadou M, Kelaini S et al. Targeting QKI-7 in vivo restores endothelial cell function in diabetes. Nat. Commun. 11(1), 3812 (2020).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print Follow us on social media for the latest updates Metrics Downloaded 229 times History Received 22 March 2022 Accepted 30 June 2022 Published online 24 August 2022 Information© 2022 The AuthorsKeywords3D printingadditive manufacturingbioprintingcardiovascular diseasestentvascular graftFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0PDF download" @default.
• W4292869368 created "2022-08-24" @default.
• W4292869368 creator A5001311671 @default.
• W4292869368 creator A5020162492 @default.
• W4292869368 creator A5031888549 @default.
• W4292869368 creator A5044907152 @default.
• W4292869368 creator A5081547013 @default.
• W4292869368 date "2022-07-01" @default.
• W4292869368 modified "2023-10-06" @default.
• W4292869368 title "3D printing for the development of implantable devices for cardiovascular disease treatment" @default.
• W4292869368 cites W1845134288 @default.
• W4292869368 cites W2185825455 @default.
• W4292869368 cites W2795325405 @default.
• W4292869368 cites W2954070504 @default.
• W4292869368 cites W2976211492 @default.
• W4292869368 cites W3042251649 @default.
• W4292869368 cites W3046132906 @default.
• W4292869368 cites W3108781053 @default.
• W4292869368 cites W3113178943 @default.
• W4292869368 cites W3124481413 @default.
• W4292869368 cites W3156565487 @default.
• W4292869368 cites W3161396539 @default.
• W4292869368 cites W3161845008 @default.
• W4292869368 cites W3164589946 @default.
• W4292869368 cites W3189555047 @default.
• W4292869368 cites W3192422468 @default.
• W4292869368 cites W3193339239 @default.
• W4292869368 cites W3199236216 @default.
• W4292869368 cites W3204455318 @default.
• W4292869368 cites W3205414397 @default.
• W4292869368 cites W4221134582 @default.
• W4292869368 cites W4281681203 @default.
• W4292869368 doi "https://doi.org/10.4155/tde-2022-0017" @default.
• W4292869368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36000225" @default.
• W4292869368 hasPublicationYear "2022" @default.
• W4292869368 type Work @default.
• W4292869368 citedByCount "0" @default.
• W4292869368 crossrefType "journal-article" @default.
• W4292869368 hasAuthorship W4292869368A5001311671 @default.
• W4292869368 hasAuthorship W4292869368A5020162492 @default.
• W4292869368 hasAuthorship W4292869368A5031888549 @default.
• W4292869368 hasAuthorship W4292869368A5044907152 @default.
• W4292869368 hasAuthorship W4292869368A5081547013 @default.
• W4292869368 hasBestOaLocation W42928693681 @default.
• W4292869368 hasConcept C126322002 @default.
• W4292869368 hasConcept C171250308 @default.
• W4292869368 hasConcept C177713679 @default.
• W4292869368 hasConcept C191897082 @default.
• W4292869368 hasConcept C192562407 @default.
• W4292869368 hasConcept C2779134260 @default.
• W4292869368 hasConcept C524769229 @default.
• W4292869368 hasConcept C71924100 @default.
• W4292869368 hasConceptScore W4292869368C126322002 @default.
• W4292869368 hasConceptScore W4292869368C171250308 @default.
• W4292869368 hasConceptScore W4292869368C177713679 @default.
• W4292869368 hasConceptScore W4292869368C191897082 @default.
• W4292869368 hasConceptScore W4292869368C192562407 @default.
• W4292869368 hasConceptScore W4292869368C2779134260 @default.
• W4292869368 hasConceptScore W4292869368C524769229 @default.
• W4292869368 hasConceptScore W4292869368C71924100 @default.
• W4292869368 hasIssue "7" @default.
• W4292869368 hasLocation W42928693681 @default.
• W4292869368 hasLocation W42928693682 @default.
• W4292869368 hasLocation W42928693683 @default.
• W4292869368 hasLocation W42928693684 @default.
• W4292869368 hasOpenAccess W4292869368 @default.
• W4292869368 hasPrimaryLocation W42928693681 @default.
• W4292869368 hasRelatedWork W1839838842 @default.
• W4292869368 hasRelatedWork W1980950179 @default.
• W4292869368 hasRelatedWork W2018919532 @default.
• W4292869368 hasRelatedWork W2024603790 @default.
• W4292869368 hasRelatedWork W2076985335 @default.
• W4292869368 hasRelatedWork W2090704721 @default.
• W4292869368 hasRelatedWork W2124125394 @default.
• W4292869368 hasRelatedWork W2315324320 @default.
• W4292869368 hasRelatedWork W2919291229 @default.
• W4292869368 hasRelatedWork W2991533465 @default.
• W4292869368 hasVolume "13" @default.
• W4292869368 isParatext "false" @default.
• W4292869368 isRetracted "false" @default.
• W4292869368 workType "article" @default.